Evidence map›Paper›PMID 37376656›Full record

ArticleViruses2023

Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.

Günalp Uzun, Rebecca Müller, Karina Althaus, Matthias Becker, Patrick Marsall, Daniel Junker, Stefanie Nowak-Harnau, Nicole Schneiderhan-Marra, Harald Klüter, Hubert Schrezenmeier and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Retrospective Analysis of Coronavirus SARS-CoV-2 Antibody Levels in COVID-19 Convalescent Plasma From Blood Donors.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Günalp UzunCentre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany.ORCID 0000-0002-8717-6230
Rebecca MüllerInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany.
Karina AlthausCentre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany.
Matthias BeckerNMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany.ORCID 0000-0002-9243-4257
Patrick MarsallNMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany.
Daniel JunkerNMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany.
Stefanie Nowak-HarnauCentre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany.ORCID 0000-0001-6785-181X
Harald KlüterInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany.
Hubert SchrezenmeierInstitute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, 89081 Ulm, Germany.
Peter BugertInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany.
Tamam BakchoulCentre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany.ORCID 0000-0002-6797-6812
Natural and Medical Sciences Institute · DEHeidelberg University · DEUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 convalescent plasma (CCP) with high neutralizing antibodies has been suggested in preventing disease progression in COVID-19. In this study, we investigated the relationship between clinical donor characteristics and neutralizing anti-SARS-CoV-2 antibodies in CCP donors. COVID-19 convalescent plasma donors were included into the study. Clinical parameters were recorded and anti-SARS-CoV-2 antibody levels (Spike Trimer, Receptor Binding Domain (RBD), S1, S2 and nucleocapsid protein) as well as ACE2 binding inhibition were measured. An ACE2 binding inhibition < 20% was defined as an inadequate neutralization capacity. Univariate and multivariable logistic regression analysis was used to detect the predictors of inadequate neutralization capacity. Ninety-one CCP donors (56 female; 61%) were analyzed. A robust correlation between all SARS-CoV-2 IgG antibodies and ACE2 binding inhibition, as well as a positive correlation between donor age, body mass index, and a negative correlation between time since symptom onset and antibody levels were found. We identified time since symptom onset, normal body mass index (BMI), and the absence of high fever as independent predictors of inadequate neutralization capacity. Gender, duration of symptoms, and number of symptoms were not associated with SARS-CoV-2 IgG antibody levels or neutralization. Neutralizing capacity was correlated with SARS-CoV-2 IgG antibodies and associated with time since symptom onset, BMI, and fever. These clinical parameters can be easily incorporated into the preselection of CCP donors.

Indexed as

COVID-19Angiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBlood DonorsCOVID-19 SerotherapyFemaleHumansImmunization, PassiveImmunoglobulin GSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 convalescent plasmaneutralizing antibodySARS-CoV-2

Identifiers

PMID37376656
PMCPMC10301943
OpenAlexW4380486420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.